Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model
Michal Hayun(Rambam Health Care Campus), Benjamin Sredni(Bar-Ilan University), Hagar Saida(Bar-Ilan University), Nechama Haran‐Ghera(Weizmann Institute of Science), Michael Albeck(Bar-Ilan University), Alpha Peled(Weizmann Institute of Science)
Cited by 18
Related Papers
Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia
|Leukemia|2019|70
Characterization and activity of sonochemically-prepared BSA microspheres containing Taxol – An anticancer drug
|Ultrasonics Sonochemistry|2007|58
The immunomodulator AS101 induces growth arrest and apoptosis in Multiple Myeloma: Association with the Akt/Survivin pathway
|Biochemical Pharmacology|2006|51
Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy
|Molecular Cancer Research|2019|34
Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the “3 + 7” induction regimen for acute myeloid leukemia
|American Journal of Hematology|2015|29